Welcome to our dedicated page for Nuvalent SEC filings (Ticker: NUVL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nuvalent, Inc. filings document a clinical-stage oncology company developing small-molecule inhibitors for clinically proven kinase targets. Its Form 8-K reports disclose operating and financial results, pipeline and clinical-trial updates for zidesamtinib and neladalkib, FDA submission events, material-event disclosures, and royalty or revenue-share arrangements for its investigational product candidates.
Proxy materials cover annual meeting governance, executive compensation, equity awards, and shareholder voting matters. Other disclosures describe Nuvalent's Class A common stock, capital-structure matters, research and development spending, cash resources, and regulatory considerations associated with advancing ROS1-, ALK-, and HER2-directed cancer programs.
NUVL registers 90,000 Class A Common shares related to a stock option exercise effective 06/08/2026.
The filing lists the method as cash and identifies the transaction type as a stock option exercise with shares to be sold through J.P. Morgan Securities LLC. The excerpt also reports two prior dispositions by James Richard Porter of 30,000 shares each on 04/06/2026 and 05/04/2026, with post-sale positions shown as 3,113,217 and 3,050,772, respectively.
Nuvalent, Inc. Chief Financial Officer Alexandra Balcom reported a mix of stock sales and an option exercise in Class A Common Stock. On June 1, 2026, she sold a total of 11,430 shares in multiple open-market transactions at weighted average prices within ranges from $94.48 to $104.19 per share under a pre-arranged Rule 10b5-1 trading plan adopted on December 23, 2025.
On the same date, she exercised stock options to acquire 11,430 shares at an exercise price of $6.89 per share. Following these transactions, Balcom directly owned 96,963 shares of Nuvalent Class A Common Stock, indicating she retained a substantial equity position after the activity.
Nuvalent, Inc.’s Chief Development Officer, Darlene Noci, reported a combination of option exercise and share sales in Class A Common Stock. On May 28, 2026, she exercised stock options to acquire 5,500 shares at an exercise price of $27.85 per share and sold 5,500 shares in open-market transactions.
The sales occurred in multiple trades at reported weighted average prices including $109.76, $109.30, $108.01, $107.33, and $106.26 per share. According to a footnote, these transactions were carried out under a Rule 10b5-1 trading plan adopted on November 18, 2024, indicating they were pre-arranged rather than timed discretionarily.
Nuvalent, Inc.’s Chief Legal Officer Deborah Ann Miller reported an exercise-and-sell transaction involving 5,500 shares of Class A Common Stock. On May 28, 2026, she exercised stock options for 5,500 shares at an exercise price of $6.89 per share and sold 5,500 shares in multiple open-market trades at weighted average prices between approximately $105.87 and $109.76 per share pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on November 18, 2024.
Following these transactions, she directly holds 59,634 shares of Nuvalent Class A Common Stock, indicating she retains a substantial equity position while monetizing part of her stake using fully vested options.
Nuvalent, Inc. reported a net loss of $109.3 million for the quarter ended March 31, 2026, wider than the $84.6 million loss a year earlier, as it accelerated R&D and commercial preparation. Research and development expenses rose to $83.6 million, while general and administrative costs increased to $35.8 million, reflecting higher headcount, stock-based compensation and launch planning.
The company remains pre-revenue and focused on oncology programs led by zidesamtinib, neladalkib and NVL‑330. It ended the quarter with $1.3 billion in cash, cash equivalents and marketable securities and believes this will fund operations into 2029, despite an accumulated deficit of about $1.1 billion.
Nuvalent, Inc. reported first quarter 2026 results and highlighted major regulatory milestones for its lung cancer pipeline. Cash, cash equivalents and marketable securities were $1.3 billion as of March 31, 2026, and the company expects this to fund operations into 2029.
For the quarter, Nuvalent recorded a net loss of $109.3 million, with research and development expenses of $83.6 million and general and administrative expenses of $35.8 million. An NDA for neladalkib in ALK-positive NSCLC was submitted, and the NDA for zidesamtinib in ROS1-positive NSCLC is under FDA review with a PDUFA target action date of September 18, 2026.
Nuvalent, Inc. President and CEO James Richard Porter reported an exercise-and-sell transaction involving the company’s Class A common stock. On May 4, 2026, he exercised stock options to acquire 30,000 shares at $18.93 per share, then sold 30,000 shares in open-market trades.
The sales occurred in multiple transactions at weighted average prices between about $98.28 and $103.05, executed pursuant to a Rule 10b5-1 trading plan adopted on December 4, 2025. Following these transactions, Porter directly holds 354,879 shares of Class A common stock and 178,686 stock options expiring on January 4, 2032.
FMR LLC filed an amendment to Schedule 13G/A reporting 9,252,159.10 shares of Nuvalent Inc. Class A common stock, representing 12.6% of the class. The filing lists sole dispositive power of 9,252,159.10 shares and sole voting power of 9,236,172. The filing names Abigail P. Johnson in relation to the holding and references an attached 13d-1(k) agreement in Exhibit 99.
Nuvalent, Inc. Chief Financial Officer Alexandra Balcom reported a mix of stock option exercises and share sales in Class A common stock. On May 1, 2026, she exercised options to acquire a total of 11,430 shares through two transactions at exercise prices of $6.89 and $1.08 per share.
On the same date, Balcom sold an aggregate of 11,430 shares in open-market transactions at weighted average prices of about $98–$100 per share, with individual sale prices ranging from $97.84 to $100.36. The filing notes these trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 23, 2025, indicating the timing of the sales was set in advance.
Nuvalent, Inc. Chief Legal Officer Deborah Ann Miller exercised stock options and sold shares in a planned transaction. On April 30, 2026, she sold 1,082 Class A common shares at a weighted average price of $99.57 and 4,418 shares at a weighted average price of $99.13 in open-market sales.
On the same date, she exercised options to acquire 5,500 Class A common shares at an exercise price of $6.89 per share from a fully vested option grant. After these transactions, she directly holds 59,634 Class A common shares. The sales were made pursuant to a Rule 10b5-1 trading plan adopted on November 18, 2024.